

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from January/February 2017

For further details see *PACE Bulletin* Volume 11 Number 6 (March 2017)

Device, Dressing or Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Apremilast 10mg, 20mg and 30mg tablets (<i>Otezla</i>) (Celgene)	For the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or PUVA (psoralen and ultraviolet-A light).	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> for this indication.
Dapagliflozin 5mg and 10mg tablets (<i>Forxiga</i>) (AstraZeneca)	For use in adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or in combination with other glucose-lowering medicinal products including insulin.	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> for all indications.
Dapagliflozin 5mg/metformin 850mg and 5mg/metformin 1000mg tablets (<i>Xigduo</i>) (AstraZeneca)	For use in adults with type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with insulin or other antidiabetic drugs.	GREEN Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> for all indications.
Eflornithine 11.5% cream (<i>Vaniqa</i>) (Almirall)	Licensed for the treatment of facial hirsutism in female adolescents (aged 12 to 18 years) and adult women.	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
Eflornithine 11.5% cream (<i>Vaniqa</i>) (Almirall)	For the treatment of facial hirsutism in patients undergoing or having undergone gender dysphoria treatments.	AMBER without shared care. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> subject to initiation or recommendation by a Gender Identity Clinic (GIC). <i>Vaniqa</i> is not licensed for this indication.
<i>Fluarix Tetra</i> inactivated quadrivalent influenza vaccine (GlaxoSmithKline)	Influenza immunisation	Not recommended for use in adults: RED-RED. Designated GREEN for use in children under 18 years. Approved for use through the <i>Lincolnshire Joint Formulary</i> solely for this indication
<i>Fluenz Tetra</i> nasal spray (AstraZeneca)	Influenza prophylaxis	GREEN Included in the <i>Lincolnshire Joint Formulary</i> . Not recommended for use in adults aged 18 years and over.
<i>Guanfacine (Intuniv)</i> 1mg, 2mg 3mg and 4mg modified release tablets (Shire)	For the treatment of Attention Deficit Hyperactivity Disorder in children aged 6 to 17 years when response to stimulants is inadequate or when stimulants are unsuitable or not tolerated.	RED-RED Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i> ; exceptions may be granted subject to a successful Individual Funding Request.

Tiotropium 10microgram inhalation powder (<i>Braltus</i>) plus delivery device (<i>Zonda</i> inhaler) (Teva Ltd)	For use in adults as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).	GREEN. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> as a lower cost alternative to the <i>Spiriva Handihaler</i> .
---------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------

This *Bulletin* has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and other PACEF publications are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>). Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Cathy Johnson on cathy.johnson@nhs.net or catherine.johnson@optum.com

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine. The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION.